LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

Accueil・Liste d'Actions・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Fermé

Secteur Soins de santé

14.55 -1.36

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.53

Max

14.89

Chiffres clés
By Trading Economics
Revenu	17M 33M
Ventes	36M 242M
BPA	0.2
Marge bénéficiaire	13.797
Employés	597
EBITDA	12M 33M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+74.46 upside

Dividendes
By Dow Jones
Prochains Résultats	6 nov. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-46M 2.5B
Ouverture précédente	15.91
Clôture précédente	14.55

Sentiment de l'Actualité

By Acuity

20%

80%

31 / 390 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

14.45 / 14.92 Support & Résistance

ACADIA Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 oct. 2024, 21:55 UTC

Principaux Mouvements du Marché

McDonald's Shares Fall After CDC Says E. Coli Outbreak Linked to Quarter Pounders -- Update

22 oct. 2024, 21:48 UTC

Actualités

CDC Says E. Coli Outbreak Linked to McDonald's Quarter Pounders -- Update

22 oct. 2024, 21:37 UTC

Principaux Mouvements du Marché

DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch

22 oct. 2024, 21:30 UTC

Principaux Mouvements du Marché

McDonald's Shares Fall After CDC Says E. Coli Outbreak Linked to Quarter Pounders

22 oct. 2024, 21:12 UTC

Actualités

CDC Says E. Coli Outbreak Linked to McDonald's Quarter Pounders

22 oct. 2024, 20:52 UTC

Actualités

Résultats

Starbucks Suspends Guidance After Sales Slump Persists

22 oct. 2024, 20:49 UTC

Actualités

Résultats

Canadian National Railway Posts Higher Revenue, Lower Profit in 3Q

22 oct. 2024, 20:28 UTC

Résultats

Texas Instruments Posts Lower 3Q Revenue

22 oct. 2024, 23:24 UTC

Actualités

Résultats

Starbucks Suspends Guidance as Sales Slump Persists -- 2nd Update

22 oct. 2024, 22:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 oct. 2024, 22:53 UTC

Market Talk

CSL's R&D Update Seen as Neutral Overall -- Market Talk

22 oct. 2024, 22:46 UTC

Actualités

Meta Bans Accounts That Track Celebrity Jet Travel, Including for Zuckerberg -- WSJ

22 oct. 2024, 22:45 UTC

Actualités

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- 3rd Update

22 oct. 2024, 21:58 UTC

Actualités

Résultats

Starbucks Suspends Guidance as Sales Slump Persists -- Update

22 oct. 2024, 21:53 UTC

Actualités

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- 2nd Update

22 oct. 2024, 21:19 UTC

Actualités

Texas Instruments' Guidance Falls Short. The Stock Is Rising Anyway. -- Barrons.com

22 oct. 2024, 21:14 UTC

Actualités

Résultats

3M Produces Beat-and-Raise Earnings. The Stock Dropped. -- Barrons.com

22 oct. 2024, 21:05 UTC

Actualités

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- Update

22 oct. 2024, 20:55 UTC

Résultats

Philip Morris International Stock Surges to Record -- WSJ

22 oct. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

22 oct. 2024, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 oct. 2024, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 oct. 2024, 20:48 UTC

Actualités

McDonald's Quarter Pounders Linked to Deadly E. Coli Outbreak -- WSJ

22 oct. 2024, 20:45 UTC

Actualités

Treasury Yields Rise, S&P 500 Edges Lower After Earnings Flurry -- WSJ

22 oct. 2024, 20:45 UTC

Résultats

GE Aerospace Stock Skids Amid Commercial-Engine Concerns -- WSJ

22 oct. 2024, 20:34 UTC

Actualités

Résultats

Starbucks Stock Drops After Company Misses Earnings, Suspends Guidance -- Barrons.com

22 oct. 2024, 20:22 UTC

Résultats

Nabors: Expects 4Q U.S. Drilling Lower 48 Avg Rig Count of Approximately 68 Rigs >NBR

22 oct. 2024, 20:22 UTC

Résultats

Nabors: Expects Full-Yr Cap Expenditures of Approximately $600M, With $230M for the SANAD Newbuilds >NBR

22 oct. 2024, 20:22 UTC

Résultats

Nabors: Expects 4Q International Avg Rig Count of Approximately 84 Rigs >NBR

22 oct. 2024, 20:22 UTC

Résultats

Nabors: Expects 4Q Cap Expenditures of $230M, With $105M for the Newbuilds in Saudi Arabia >NBR

Comparaison

Variation de prix

ACADIA Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

74.46% hausse

Prévisions sur 12 Mois

Moyen 25.75 USD 74.46%

Haut 39 USD

Bas 12 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

20 ratings

Achat

Maintien

Vente

Basé sur 20 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

14.45 / 14.92Support & Résistance

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

31 / 390Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

À Propos ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).